[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363378-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-363378-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","endocrine-therapy-and-covid-19-outcomes-in-women-with-breast-cancer-a-nationwide-register-based-matched-cohort-study","Endocrine therapy and COVID-19 outcomes in women with breast cancer - a nationwide register-based matched cohort study","","The COVID-19 pandemic introduced major challenges to cancer care and raised concerns about the safety of ongoing endocrine therapy for women with breast cancer, yet population-based real-world evidence remained limited. A nationwide Swedish register-based matched cohort study evaluated women aged ≥55 receiving endocrine therapy in 2020, comparing 31,678 treated patients with age- and region-matched controls. COVID-19–related mortality and ICU admission were not increased overall, with stage-specific differences by therapy type.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/endocrine-therapy-and-covid-19-outcomes-in-women-with-breast-cancer-a-nationwide-register-based-matched-cohort-study/363378/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/endocrine-therapy-and-covid-19-outcomes-in-women-with-breast-cancer-a-nationwide-register-based-matched-cohort-study/363378.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main purpose of the nationwide study?","Question",{"text":63,"@type":64},"To evaluate whether endocrine therapy in women with breast cancer was associated with COVID-19 outcomes, including COVID-19–related mortality, during the 2020 pandemic period in Sweden.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients and controls selected and matched?",{"text":68,"@type":64},"Women aged ≥55 who received endocrine therapy for breast cancer during 2020 were included and matched 1:1 by age and region to population controls without breast cancer or estrogen-modulating therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"Did endocrine therapy increase COVID-19–specific mortality?",{"text":72,"@type":64},"No. COVID-19–related mortality did not differ between women receiving endocrine therapy and their matched population controls, and ICU admission risk was comparable across groups.",{"name":74,"@type":61,"acceptedAnswer":75},"Were results different depending on cancer stage and type of endocrine therapy?",{"text":76,"@type":64},"Yes. Tamoxifen was linked to lower all-cause mortality in early-stage breast cancer, while aromatase inhibitors were associated with higher all-cause mortality and increased COVID-19–related hospitalization in locally advanced disease.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},363378,1790840941,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,104,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Comic",60,"comic",{"id":105,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},6,"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":55,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":33,"preview_urls":150},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Schiza etal. BMC Cancer (2026) 26:598 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16152-6](https://doi.org/10.1186/s12885-026-16152-6)  \nRESEARCH Open Access  \nEndocrine therapy and COVID-19 outcomesin women with breast cancer: a nationwide register-based matched cohort study  \nAglaia Schiza1,2*, Evangelos Digkas1,2, Fotios Papadopoulos3, Alkistis Skalkidou4 and Evangelia Elenis4,5  \nAbstract  \nPurpose The COVID-19 pandemic posed substantial challenges to cancer care, raising concerns about the safety of ongoing endocrine therapy in women with breast cancer. However, real-world evidence on the association between endocrine therapy and COVID-19 outcomes in population-based cohorts remains limited.  \nMethods A nationwide, register-based matched cohort study was conducted in Sweden, including women  \naged ≥ 55 years who received endocrine therapy for breast cancer during 2020. A total of 31,678 women were included: 8,879 treated with tamoxifen, 21,384 with aromatase inhibitors, and 1,415 with sequential therapy. Exposed women were matched 1:1 by age and region to population controls without breast cancer or estrogen-modulating therapy. Stage-stratified analyses were performed for early-stage and locally advanced breast cancer. Outcomes included COVID-19–related mortality (primary outcome), all-cause mortality, intensive care unit admission, COVID-19– related hospitalization, and laboratory-confirmed SARS-CoV-2 infection.  \nResults COVID-19–related mortality did not differ between women receiving endocrine therapy and their matched population controls. Intensive care unit admission risk were comparable across groups. Tamoxifen was associated with lower all-cause mortality in early-stage breast cancer, whereas aromatase inhibitors were linked to higher all-cause mortality and increased COVID-19-related hospitalization in locally advanced disease. A modestly increased risk of SARS-CoV-2 infection was observed among tamoxifen users.  \nConclusion In this nationwide Swedish cohort, adjuvant endocrine therapy was not associated with increased COVID-19–specific mortality. These findings support the continued use of adjuvant endocrine therapy in women with breast cancer without added COVID-19 mortality risk and highlight stage-specific differences in outcomes, reinforcing the safety of endocrine therapy during pandemic conditions.  \nHighlights  \n• Nationwide Swedish study examining endocrine therapy and COVID-19 outcomes in breast cancer patients.  \n• No increased COVID-19 mortality or intensive care unit admission linked to adjuvant endocrine therapy.  \n• Tamoxifen associated with lower all-cause mortality in early-stage breast cancer.  \n• Findings support safe continuation of adjuvant endocrine therapy during the pandemic.  \n*Correspondence: Aglaia Schiza [Aglaia.schiza@igp. uu.se](Aglaia.schiza@igp. uu.se)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nSchiza et al. BMC Cancer (2026) 26:598 Page 2 of 11  \nKeywords Breast cancer, COVID-19, SARS-CoV-2, ","cbCaivqcmekEnkxi","https://ap.wps.com/l/cbCaivqcmekEnkxi","pdf",1962655,11,"English","# Abstract\n# Purpose\n# Methods\n# Results\n# Conclusion\n# Highlights\n# Keywords\n# Introduction","[{\"question\":\"What was the main purpose of the nationwide study?\",\"answer\":\"To evaluate whether endocrine therapy in women with breast cancer was associated with COVID-19 outcomes, including COVID-19–related mortality, during the 2020 pandemic period in Sweden.\"},{\"question\":\"How were patients and controls selected and matched?\",\"answer\":\"Women aged ≥55 who received endocrine therapy for breast cancer during 2020 were included and matched 1:1 by age and region to population controls without breast cancer or estrogen-modulating therapy.\"},{\"question\":\"Did endocrine therapy increase COVID-19–specific mortality?\",\"answer\":\"No. COVID-19–related mortality did not differ between women receiving endocrine therapy and their matched population controls, and ICU admission risk was comparable across groups.\"},{\"question\":\"Were results different depending on cancer stage and type of endocrine therapy?\",\"answer\":\"Yes. Tamoxifen was linked to lower all-cause mortality in early-stage breast cancer, while aromatase inhibitors were associated with higher all-cause mortality and increased COVID-19–related hospitalization in locally advanced disease.\"}]","Endocrine therapy and COVID-19 outcomes in women with breast cancer - a nationwide register-based matched cohort study | PDF",1790151000,28,[151,155,159,163],{"page_no":22,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bfd8de1ccf6f888bcea87d909d7d75d.webp",983,1310,{"page_no":26,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1658b2f1e7ef56dab60adf145246016b.webp",982,1309,{"page_no":30,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47d59c2d11ebfe4fb77d24acdc0ac72d.webp",981,1308,{"page_no":33,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/105a4ce67fe37eb5e501f82df5bb95ce.webp",980,1306]